Investigating the effect of using omega-3 on disease activity in patients with rheumatoid arthritis

Investigating the effect of using omega-3 on disease activity in patients with rheumatoid arthritis: a clinical trial study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190618043934N29

Enrollment

104

Registered

2024-11-09

Start date

2024-11-21

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis. Rheumatoid arthritis with rheumatoid factor

Interventions

Intervention 1: Intervention group: Intervention group 1: patients receiving routine treatment of rheumatoid arthritis for 3 months. Intervention 2: Intervention group: Intervention group 2: patients

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Informed consent to enter the study over 18 years of age

Exclusion criteria

Exclusion criteria: Bone abnormality Severe concomitant disease such as metabolic and gastrointestinal disease Use of omega-3 supplements Elevated serum levels or creatinine greater than 1.8 mg/dL Failure to complete the treatment course Gastrointestinal intolerance Severe infection

Design outcomes

Primary

Measure	Time frame
Severity of the disease: In order to check the severity of the disease, it is evaluated using the DAS-28 questionnaire based on the number of swollen joints, local sensitivity and sodium concentration number. Based on the score obtained from the DAS-28 questionnaire, the disease was divided into four categories: improvement (DAS_28 less than 2.6), mild (DAS_28 score between 6.2 and 3.2), moderate (DAS_28 score between 3.2 and 5.1) and severe (DAS-28 more than 5.1) are divided. Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Using the DAS-28 questionnaire.	—

Measure

Time frame

Severity of the disease: In order to check the severity of the disease, it is evaluated using the DAS-28 questionnaire based on the number of swollen joints, local sensitivity and sodium concentration number. Based on the score obtained from the DAS-28 questionnaire, the disease was divided into four categories: improvement (DAS_28 less than 2.6), mild (DAS_28 score between 6.2 and 3.2), moderate (DAS_28 score between 3.2 and 5.1) and severe (DAS-28 more than 5.1) are divided. Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Using the DAS-28 questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReza Ariaeefar

Birjand University of Medical Sciences

www.reza40740@gmail.com+98 56 3232 3232

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026